Contacts|Rss Search English | Italiano Home Who we are The group Activities Therapeutic areas Responsibilities Organization Home >> Therapeutic areas >> Immuno-oncology Back Thrombosis and critical ischemia Cardiovascular, osteoporosis and inflammation Immuno-oncology Drugs Gynecology Neurology and psychiatry Immuno-oncology The Immuno-Oncologic Therapeutic area of Italfarmaco is acknowledged by the Italian oncologic community as a reference point in the specialist sector thanks to the originality of its products, the innovative pharmaceutical solutions and the innovation of experimental protocols. Hematology and Oncology Italfarmaco has always developed products for the treatment of tumors and patient support through a constant partnership with Scientific Societies and the most qualified research groups in the oncologic area (solid tumors) as well as in the hematologic area (leukemia, myelomas, lymphomas, bone marrow transplantation). Thanks to the support offered by clinical research, the products manufactured by Italfarmaco today have a scientific literature authoritatively documenting its efficacy and safety extended to all these clinical settings. MYELOSTIM® (lenograstim) is the only glycosylated granulocyte growth factor, indistinguishable from the native human one, effectively enabling to prevent and control bone marrow toxicity caused by the use of chemotherapeutic agents producing neutropenia, and thus facilitating its administration according to the time and doses as scheduled by the specialist. Treatment of tumors The company has a well-established experience and expertise in the therapeutic area of endocrinology and neuroendocrine tumors, thanks to the octreotide-based medicinal products. The different pharmaceutical formulations (e.g. pre-filled syringes - TREOJECT®) and different dosage strengths and schedules as well ensure a maximum clinical efficacy and aid patients’ adherence to treatment protocols. Supportive care in oncology and hematology Nausea, vomiting, serious chronic pain and neutropenia, causing frequent, often fatal infections, represent the feared and severe complications of chemotherapeutic treatment in patients with tumors, resulting in a worsened Quality of Life or the impossibility of continuing their medical treatment. AKYNZEO® (netupitant/palonosetron) is the first and only fixed-dose antiemetic in combining the new NK-1 antagonist netupitant with the sole antagonist of the second generation of serotonin, palonosetron, already marketed by Italfarmaco since 2006 as ALOXI®. Thanks to its totally innovative oral formulation and to the characteristics of its active ingredients, which act in a synergistic and long acting way, AKYNZEO® is able to ensure the highest levels of safety and efficacy in the prevention of nausea and vomiting, with a single dose ready to use, administered before cancer chemotherapy. AKYNZEO® so simplifies the management of antiemetic prophylaxis and facilitates better compliance with the recommendations of the major international guidelines on the prevention of nausea and vomiting from chemotherapy. For the treatment of severe chronic pain, Italfarmaco has introduced the first transdermal patch patented with double matrix (FENTALGON®), studied to improve the release of the active ingredient and ensure pain control until 72 hours after application. The Immuno-oncologic therapeutic area of Italfarmaco has always been acknowledged for its innovative products and its constant support to clinical research aimed at optimizing tumor response to treatment and give patients the best possible life conditions. CONTACTS WRITE AN E-MAIL OUR OFFICES SUBMIT YOUR CV MAIN OFFICES AND FACTORY ITALFARMACO S.p.A. V.le Fulvio Testi, 330 20126 Milan Tel. 02 64431 Fax 02 644346 / 02 66102753 DIRECTION, OFFICES AND RESEARCH CENTER ITALFARMACO S.p.A. Via dei Lavoratori, 54 20092 Cinisello Balsamo (MI) Tel. 02 64431 Fax 02 6424790 LEGAL NOTES PRIVACY POLICY COOKIE POLICY TERMS OF USE © Copyright 2015-2020 by ITALFARMACO S.p.A. | all rights reserved | Revenue Number and VAT number 00737420158 Companies' Register of Milan R.E.A. 273567| Fully paid stock capital €13.000.000 Powered by This website uses technical session and function cookies in order to enable its sure and efficient exploration. Furthermore, the website also uses analytical third parties cookies (Google Analytics), to collect in an aggregate way information on the navigation of the users performed on the website. If you want more information or to object to the entry of the cookies, please read our Cookies Policy inside the information notice on Privacy of this website. Closing this banner or accessing any underlying element of the website, you accept the use of the cookies. Read the Cookies PolicyOK